Related Experiment Video
Updated: Jul 31, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
Moo-Kon Song1, Byeong-Bae Park2, Ji-Eun Uhm2
1Department of Hematology-Oncology, Hanyang University Hanmaeum Changwon Hospital, Changwon 51497, Korea.
Abstract:
FLT3 mutations are the most common genomic alteration detected in acute myeloid leukemia (AML) with a worse clinical prognosis. The highly frequent FLT3 mutations, together with the side effects associated with clinical prognosis, make FLT3 promising treatment targets and have provoked the advancement of FLT3 inhibitors. Recently, numerous FLT3 inhibitors were actively developed, and thus the outcomes of this aggressive subtype of AML were significantly improved. Recently, midostaurin and gilteritinib were approved as frontline treatment of AML and as therapeutic agents in the recurred disease by the United States Food and Drug Administration. Recently, numerous promising clinical trials attempted to seek appropriate management in frontline settings, in relapsed/refractory disease, or after stem cell transplantation in AML. This review follows numerous clinical trials about the usefulness of FLT3 inhibitors as frontline therapy, as relapsed/refractory conditioning, and as maintenance therapy of stem cell transplantation. The cumulative data of FLT3 inhibitors would be important clinical evidence for further management with FLT3 inhibitors in AML patients with FLT3 mutations.
Insights
FLT3 inhibitors show promise in treating acute myeloid leukemia (AML) with FLT3 mutations. This review examines clinical trials on FLT3 inhibitors for frontline, relapsed/refractory, and post-transplant AML management.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML), associated with poor prognosis.
- FLT3 mutations present a significant therapeutic target due to their prevalence and impact on clinical outcomes.
Purpose of the Study:
- To review clinical trials evaluating FLT3 inhibitors in various AML settings.
- To assess the efficacy of FLT3 inhibitors as frontline therapy, for relapsed/refractory disease, and as post-stem cell transplantation maintenance.
Main Methods:
- Systematic review of clinical trials involving FLT3 inhibitors in AML.
- Analysis of data from studies focusing on frontline, relapsed/refractory, and maintenance settings.
Main Results:
- FLT3 inhibitors have improved outcomes for AML patients with FLT3 mutations.
- Midostaurin and gilteritinib are approved treatments for frontline and relapsed/refractory AML.
- Ongoing trials explore optimal use in diverse AML patient populations.
Conclusions:
- FLT3 inhibitors represent a crucial advancement in AML treatment.
- Cumulative data support the use of FLT3 inhibitors for managing FLT3-mutated AML.
- Further evidence from clinical trials will guide future treatment strategies.
